RecruitingPhase 1NCT06941129

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases

Studying Anti-neutrophil cytoplasmic antibody-associated vasculitis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Intervention
UCAR T-cell(biological)
Enrollment
12 enrolled
Eligibility
18 years · All sexes
Timeline
20252028

Study locations (1)

Collaborators

Shanghai Xiniao Biotech Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06941129 on ClinicalTrials.gov

Other trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis

Additional recruiting or active studies for the same condition.

See all trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis

← Back to all trials